Touchlight at Cell & Gene Therapy Europe
Touchlight are delighted to announce we will be presenting at Cell & Gene Therapy Europe. The conference in Barcelona begins on 29th September 2015, where we will discuss our regulatory and logistic solutions to key issues facing the commercialisation of cell and gene therapies.
- ENDS -
Touchlight is a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact:
|Karen Fallen, Chief Executive Officer||Instinctif|
|Robin Bodicoat, Head of Marketing||E: email@example.com|
|E: firstname.lastname@example.org||T: +44 20 7457 2020|
|T: +44 20 8481 9200|